Biotechnology

Galapagos NV

Galapagos NV released FY2026 Q1 earnings on May 6 After-Market EST, actual revenue USD 7.427 M, actual EPS USD 0.2521

Galapagos NV to Release FY2026 Q1 Earnings on May 6 After-Market EST, Forecast Revenue USD 28.74 M, EPS USD -1.5083

Galapagos and Gilead Sign Binding Agreement for the Acquisition of Ouro Medicines for $170 Million

Galapagos NV to Release FY2025 Earnings on March 26 Pre-Market EST, Forecast Revenue USD 328.88 M, EPS USD -8.3822

Galapagos NV released FY2025 Annual Earnings on February 23 Pre-Market (EST), actual revenue USD 1.282 B (forecast USD 328.88 M), actual EPS USD 5.6112 (forecast USD -8.3822)

Galapagos NV released FY2025 Q4 earnings on February 23 Pre-Market (EST), actual revenue USD 1.058 B (forecast USD 83.8 M), actual EPS USD 13.9381 (forecast USD -0.1526)

Galapagos NV Decides to End Cell Therapy Business

Barclays Analyst Maintains Sell Rating on Galapagos

US Bank Securities Maintains Sell Rating on Galapagos

Galapagos NV released FY2025 Q3 earnings on November 5 (EST), actual revenue USD 83.45 M (forecast USD 81.02 M), actual EPS USD -3.5977 (forecast USD -0.5668)

Galapagos NV released FY2025 9 Months earnings on November 5 (EST), actual revenue USD 241.04M, actual EPS USD -7.9967

dombu's Focus on Healthcare Industry Stocks

Galapagos NV to Release FY2025 Q3 Earnings on November 5, 2025 (EST), Forecast Revenue USD 80.37 M, EPS USD -0.5622

Galapagos NV released FY2025 Q2 earnings on July 23 (EST), actual revenue USD 76.42 M (forecast USD 82.55 M), actual EPS USD -1.8767 (forecast USD -0.1638)

Galapagos NV released FY2025 Semi-Annual Earnings on July 23 Post-Market (EST), with actual revenue of USD 158.01 M and EPS of USD -4.4302

Galapagos NV Reports Widened Net Loss in H1 2025

Galapagos NV to Release FY2025 Semi-Annual Earnings on July 22, 2025 (EST)

Galapagos NV Appoints Aaron Cox as CFO

Galapagos NV Expands GLPG5101 Development Plan

Galapagos NV Displays Positive Data on CD19 CAR T Cell Therapy GLPG5101

Netcapital

Agape ATP

Tradr 2X Long QBTS Daily ETF

Akanda

Defiance Daily Target 2X Long RGTI ETF

PicoCELA

Tradr 2X Long RGTI Daily ETF

Co-Diagnostics

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NewGenIvf

Ticker Change

代码变更

From 2026.05.08 (EST) changed to LKFT

GLPG

ARKG

SBIO

LABU

LKFT

Galapagos NV shareholders approved a name change to Lakefront Biotherapeutics and a governance overhaul during their meetings on April 28, 2026. Key changes include the appointment of CEO Henry Gosebruch as executive director, new independent directors, and a renewed focus on sustainability reporting. The board was authorized to repurchase shares and increase capital by 20%. The company aims to support its transformation and growth phase, with Gino Santini as the new chair. Current analyst rating for GLPG stock is a Hold with a price target of $28.00.

Tip Ranks

VanEck Biotech ETF

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

VG Health

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

Lakefront Biotherapeutics

Galapagos Shareholders Approve Name Change to Lakefront Biotherapeutics and Broad Governance Overhaul

Galapagos (NASDAQ:GLPG) is set to announce its Q1 2026 earnings on May 6, with analysts expecting a loss of $0.13 per share and revenue of $39.58 million. The company reported $13.92 EPS and $1.06 billion revenue in its last quarter. Currently, GLPG stock is trading at $28.42, with a market cap of $1.87 billion. Analysts have mixed ratings, with one Strong Buy, five Holds, and one Sell. Institutional investors hold 32.46% of the stock, reflecting increased interest in the company.

Market Beat

ROYAL BANK OF CANADA

UBS Group AG

Raymond James Financial

Man Group PLC

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

Galapagos (GLPG) Expected to Announce Quarterly Earnings on Wednesday

Mechelen, Belgium - April 28, 2026 - Galapagos NV disclosed that during the Annual and Extraordinary Shareholders’ Meetings on April 28, 2026, all resolutions put forth were successfully passed. Galapagos NV, listed on Euronext and NASDAQ under the ticker symbol GLPG, confirmed the approval of all proposed resolutions during the meetings.

Unusual Whales

Galapagos’ Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders’ Meetings 2026

Galapagos NV (NASDAQ:GLPG) experienced a 20.4% increase in short interest in March, totaling 1,096,114 shares as of March 31. This represents 1.7% of the company's stock being short sold, with a short-interest ratio of 5.0 days based on an average daily volume of 218,377 shares. The stock traded at $29.28, with a market cap of $1.93 billion. Analysts have mixed ratings, with a consensus rating of "Hold" and a target price of $36.50. Institutional investors own 32.46% of the stock, reflecting significant interest in the company.

Ameriprise Financial

MarketWise

Short Interest in Galapagos NV (NASDAQ:GLPG) Expands By 20.4%

Galapagos NV (NASDAQ:GLPG) shares fell below their 200-day moving average of $32.63, trading at $28.93. Analysts have mixed opinions, with one Strong Buy, five Holds, and one Sell rating. The average target price is $36.50. The company reported $13.92 EPS and $1.06 billion in revenue last quarter. Institutional investors hold 32.46% of the stock. Galapagos focuses on developing small-molecule therapies for chronic diseases and has a market cap of $1.91 billion.

Galapagos (NASDAQ:GLPG) Stock Crosses Below 200 Day Moving Average   - Time to Sell?

Galapagos has entered a binding framework agreement with Gilead Sciences related to Gilead's $1.675 billion acquisition of Ouro Medicines. This deal involves co-developing gamgertamig, a T cell engager for autoimmune diseases, with Galapagos funding 50% of the acquisition and development costs. Gilead will handle global commercialization outside certain territories, paying Galapagos tiered royalties. The agreement allows Galapagos to utilize $500 million independently for strategic moves, including potential share buybacks. Analysts rate GLPG stock as a Buy with a $32.00 price target, while Spark's AI Analyst gives it a Neutral rating due to financial concerns.

iShares Global Healthcare

Gilead Sciences

Galapagos Strikes New Gilead Deal to Co-Develop Gamgertamig and Unlock $500 Million for Strategic Moves

Galapagos NV(GLPG.US)

Galapagos Shareholders Approve Name Change to Lakefront Biotherapeutics and Broad Governance Overhaul

Galapagos (GLPG) Expected to Announce Quarterly Earnings on Wednesday

Galapagos’ Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders’ Meetings 2026

Short Interest in Galapagos NV (NASDAQ:GLPG) Expands By 20.4%

Galapagos (NASDAQ:GLPG) Stock Crosses Below 200 Day Moving Average - Time to Sell?

Galapagos Strikes New Gilead Deal to Co-Develop Gamgertamig and Unlock $500 Million for Strategic Moves

Trending